Xvivo Perfusion AB (LTS:0RKL) EPS (Basic): kr2.82 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKL Xvivo Perfusion AB LTS:0RKL
84 GF Score
Price kr235.11
GF Value kr402.16
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB EPS (Basic)?

Xvivo Perfusion AB LTS:0RKL -9.09% 84 EPS (Basic) is kr2.82 as of Jun. 2026. GuruFocus rates LTS:0RKL with a GF Score™ of 84/100 and a GF Value™ of kr402.16 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Xvivo Perfusion AB's basic earnings per share (Basic EPS) for the three months ended in Jun. 2026 was kr0.52. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was kr2.82.

Xvivo Perfusion AB's EPS (Diluted) for the three months ended in Jun. 2026 was kr0.52. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was kr2.82.

Xvivo Perfusion AB's EPS without NRI for the three months ended in Jun. 2026 was kr0.52. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was 2.82.

During the past 12 months, Xvivo Perfusion AB's average EPS without NRIGrowth Rate was -19.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Xvivo Perfusion AB's highest 3-Year average EPS without NRI Growth Rate was 168.90% per year. The lowest was -42.60% per year. And the median was 17.40% per year.

Xvivo Perfusion AB  (LTS:0RKL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Xvivo Perfusion AB EPS (Basic) Related Terms

Xvivo Perfusion AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB EPS (Basic) Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.62 3.07 5.47 0.80

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.14 1.01 1.15 0.52
LTS:0RKL
84GF Score
Xvivo Perfusion AB LTS:0RKL
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Xvivo Perfusion AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(25.163-0)/31.499
=0.80

Xvivo Perfusion AB's Basic EPS for the quarter that ended in Jun. 2026 is calculated as

Basic EPS (Q: Jun. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(16.282-0)/31.499
=0.52

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr2.82 mean?
Xvivo Perfusion AB (LTS:0RKL) has a EPS (Basic) of kr2.82 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's EPS (Basic) too high?
Xvivo Perfusion AB's current EPS (Basic) is kr2.82. Overall, Xvivo Perfusion AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EPS (Basic) compare to ABT and SYK?
Xvivo Perfusion AB's EPS (Basic) of kr2.82 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current EPS (Basic) is kr2.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (LTS:0RKL) is currently considered Significantly Undervalued. The stock's GF Value™ is kr402.16, compared to a current price of kr235.11 — trading 41.5% below its estimated fair value. The current EPS (Basic) is kr2.82. Xvivo Perfusion AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Xvivo Perfusion AB (LTS:0RKL), the current EPS (Basic) is kr2.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (LTS:0RKL) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of kr235.11 is trading 41.5% below its estimated GF Value™ of kr402.16. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for LTS:0RKL:

  • EPS (Basic): kr2.82
  • GF Value™: kr402.16 vs. price of kr235.11 (41.5% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
84GF Score

Get the complete analysis for LTS:0RKL

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr235.11
Price
kr402.16
GF Value